Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO versus IVIg for severe sepsis-associated thrombocytopenia
ChiCTR-IPR-15006986Phase 4Recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Sep 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human thrombopoietin and Human normal immunoglobulin G in sepsis and Thrombocytopenia (2 arms), sponsored by Tianjin First Central Hospital. Primary endpoints: Complete blood count and Blood biochemistry. Started Sep 2011; status: recruiting.
02
Drugs
recombinant human thrombopoietinHuman normal immunoglobulin G
03
Conditions
sepsisThrombocytopenia
Beyond the preview
Go deeper on ChiCTR-IPR-15006986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006986.